With Bayer predicting slowdowns for Xarelto and Eylea, what will fill the gap? - FiercePharma

With Bayer predicting slowdowns for Xarelto and Eylea, what will fill the gap?  FiercePharma

Bayer's Xarelto and Eylea are still the top performers within the company's pharma business. But both drugs are looking at a bumpy road ahead.



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more